EIF1AXP1: A Potential Drug Target and Biomarker (G280661)

Target Name: EIF1AXP1

NCBI ID: G280661

EIF1AXP1

Other Name(s): EIF1AX pseudogene 1 | EIF1AP1 | Eukaryotic translation initiation factor 1A, X-linked pseudogene 1

EIF1AXP1: A Potential Drug Target and Biomarker

EIF1AXP1, also known as EIF1AX pseudogene 1, is a gene that has been identified in various human cancers, including breast, ovarian, and colorectal cancers. Its function and potential clinical applications continue to be under investigation. In this article, we will explore the potential drug target and biomarker properties of EIF1AXP1.

Potential Drug Target

The EIF1AX family is a group of transmembrane proteins that are involved in various cellular processes, including cell signaling, DNA replication, and apoptosis. EIF1AXP1 is a pseudogene, which means that it encodes a protein that is similar to a gene that is already known to have a function in the cell.

EIF1AXP1 has been shown to play a role in cell signaling, specifically in the regulation of the T-cell receptor (TCR) signaling pathway. This pathway is involved in the development and activation of T-cells, which are a crucial part of the immune system.

Research has shown that EIF1AXP1 is a negative regulator of the T-cell receptor signaling pathway, which means that it keeps the T-cell receptor signaling pathway in a state of inactivation. This contributes to the inhibition of immune responses, which may contribute to the development of cancer.

Potential Biomarker

EIF1AXP1 has also been shown to be a potential biomarker for cancer, specifically for breast and ovarian cancers. The expression of EIF1AXP1 has been shown to be elevated in breast and ovarian cancer tissues, and it has been used as a biomarker for these cancers in various clinical trials.

One of the challenges in the development of EIF1AXP1 as a biomarker is its limited expression in some cancer types. For example, EIF1AXP1 is not expressed in most solid tumors, which limit its utility as a biomarker. Additionally, the expression of EIF1AXP1 may be influenced by factors such as cancer stage, which can affect the amount of EIF1AXP1 available in the tumor.

Despite these challenges, research has shown that EIF1AXP1 can be used as a potential biomarker for breast and ovarian cancers. This is an exciting area of research, as the development of new biomarkers for cancer has the potential to improve diagnostic accuracy and treatment outcomes.

Conclusion

In conclusion, EIF1AXP1 is a pseudogene that has been shown to play a role in cell signaling and contribute to the development of cancer. Its potential as a drug target and biomarker continues to be investigated. Further research is needed to fully understand its role in cancer development and its potential as a therapeutic target.

Protein Name: EIF1AX Pseudogene 1

The "EIF1AXP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF1AXP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets